To assess whether EMP occured during the transition from in situ to invasive stage in ER+ BC, we measured CDH1 and EMT-TFs expression 1 month after intraductal injection of MCF-7 cells, when primary tumors were in situ, and at 5 months, when they were invasive (Fig. 4a). This evidence concerns the gene CDH1 and breast cancer.